Akari CEO Says Synthetic Royalties May Be Used To Fund Coversin Trials
Executive Summary
Akari Therapeutics will explore novel funding options to pay for Phase III trials of Coversin, its lead asset, derived from a native protein discovered in the saliva of the Ornithodoros moubata tick.
You may also be interested in...
Alexion Looks To Broaden Complement Inhibitor Market With Next-Generation Ultomiris
Positive late-stage clinical results involving Ultomiris in a second potential indication suggest Alexion is on the right track to develop new ultra-rare disease therapies with significant commercial potential.
Alexion CEO Hantson Tasked With Kicking Growth Momentum Into Gear
The rare disease specialist’s new CEO is former Baxalta CEO Ludwig Hantson, who takes over the helm immediately after a leadership shakeup coinciding with an audit investigation.
Patient-Centric: Evotec’s CSO Explains R&D Strategy
Evotec’s multimodality approach to drug discovery landed the biotech two new discovery collaborations this week, underscoring its emphasis on patient-driven data.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports